CTOs on the Move

PMV Pharmaceutcals

www.pmvpharma.com

 
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Shibu Sleeba
 Vice President, Information Technology Profile

Funding

PMV Pharmaceutcals raised $104M on 02/23/2017
PMV Pharmaceutcals raised $74M on 02/23/2017
PMV Pharmaceutcals raised $62M on 11/13/2019
PMV Pharmaceutcals raised $70M on 08/03/2020

Similar Companies

Pharmascience

Leader in the manufacture of generic drugs, we produce and distribute brand name drugs and over-the-counter drugs. Based in Montreal, Canada, we have about 1 500 employees. Our products are sold in more than sixty countries. Our portfolio of 340 products cumulates 2000 different dosage strengths. We invest $ 30 million per year in research and development. We firmly believe that we must be an example in our community. We support many charities, here as elsewhere. For international humanitarian purposes, we have donated products valued at approximately $ 23.5 million over the past five years.

TWG Market Research

TWG Market Research is a Barrington, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AzoRx

AzoRx, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coldstream Laboratories

Coldstream Laboratories is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.